These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 3045026

  • 1. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease.
    Sabbá C, Zupo V, Dina F, Nazzari M, Albano O.
    Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):249-52. PubMed ID: 3045026
    [Abstract] [Full Text] [Related]

  • 2. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
    Marrapodi E, Leanza D, Giordano S, Nazzari M, Corsi C.
    Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A, Fareed J, Sabbá C, Albano O, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Arpaia MR.
    Semin Thromb Hemost; 1991 Apr; 17 Suppl 2():228-34. PubMed ID: 1948094
    [Abstract] [Full Text] [Related]

  • 4. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E, Pancera P, Zannoni M, Arcaro G, Priante F, Lechi A.
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [Abstract] [Full Text] [Related]

  • 5. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
    Violi F, Marubini E, Coccheri S, Nenci GG.
    Thromb Haemost; 2000 May; 83(5):672-7. PubMed ID: 10823260
    [Abstract] [Full Text] [Related]

  • 6. Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD).
    Craveri A, Tornaghi G, Ranieri R, Stanzani M, Landi G, Paganardi L, Passaretti B, Gallo E.
    Int Angiol; 1990 May; 9(4):274-7. PubMed ID: 2099963
    [Abstract] [Full Text] [Related]

  • 7. [Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500-15000 dalton)].
    Michelini S, Micci A, Failla A, Grechi G, Iantaffi A.
    Minerva Cardioangiol; 1996 May; 44(1-2):33-7. PubMed ID: 8767620
    [Abstract] [Full Text] [Related]

  • 8. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study.
    Laurora G, Ambrosoli L, Cesarone MR, De Sanctis MT, Incandela L, Marelli C, Belcaro G.
    Panminerva Med; 1994 Jun; 36(2):83-6. PubMed ID: 7831064
    [Abstract] [Full Text] [Related]

  • 9. [Prevention of deep venous thrombosis with defibrotide in chest surgery. Controlled multicenter study versus heparin].
    Rizzi A, Radaelli F, Pisano M, Orro S, Nazzari M, Ratti G, Giobbe R, Maggi G.
    Minerva Med; 1987 Jun 15; 78(11):745-50. PubMed ID: 3295599
    [Abstract] [Full Text] [Related]

  • 10. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease.
    Belfiglio A, Traietti P, Bologna E, Salvo G.
    Clin Ther; 1989 Jun 15; 11(4):479-84. PubMed ID: 2776165
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
    Marci M, Albiani B, Ricci M, Russo F.
    Clin Ter; 1995 Mar 15; 146(3):211-4. PubMed ID: 7789083
    [Abstract] [Full Text] [Related]

  • 12. Effects of defibrotide in patients with chronic deep insufficiency. The PROVEDIS study.
    Coccheri S, Andreozzi GM, D'Addato M, Gensini GF, PROVEDIS Study Group.
    Int Angiol; 2004 Jun 15; 23(2):100-7. PubMed ID: 15507885
    [Abstract] [Full Text] [Related]

  • 13. Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide.
    Cimminiello C, Milani M, Pietra A, Rossi F, Aloisio M, Nazzari M, Bonfardeci G.
    Semin Thromb Hemost; 1991 Jun 15; 17 Suppl 1():106-11. PubMed ID: 2068563
    [Abstract] [Full Text] [Related]

  • 14. Effects of defibrotide on peripheral obliterative vascular diseases.
    Ulutin ON, Ilhan-Berkel N, Tunali H, Ozer M, Balkuv-Ulutin S, Onsel C, Urgancioğlu I.
    Haemostasis; 1986 Jun 15; 16 Suppl 1():59-62. PubMed ID: 3754837
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
    Riccioni C, Sarcinella R, Palermo G, Izzo A, Liguori M, Koverech A, Messano M, Virmani A.
    Int Angiol; 2008 Jun 15; 27(3):253-9. PubMed ID: 18506129
    [Abstract] [Full Text] [Related]

  • 16. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency.
    Bauer U.
    Arzneimittelforschung; 1984 Jun 15; 34(6):716-20. PubMed ID: 6386008
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of defibrotide for prophylaxis of deep venous thrombosis in gynecological surgery: a double-blind, placebo-controlled clinical trial.
    Ciavarella N, Ettorre C, Schiavoni M, Schonauer S, Cicinelli E, Cagnazzo G.
    Haemostasis; 1986 Jun 15; 16 Suppl 1():39-41. PubMed ID: 3754834
    [Abstract] [Full Text] [Related]

  • 18. [Defibrotide versus heparin in antithrombotic prophylaxis in gynecological surgery].
    Lippi G, Viliani T, Alessandrello-Liotta A, Morelli P, Zucconi G, Doni A, Gerosa C.
    Minerva Med; 1989 May 15; 80(5):455-9. PubMed ID: 2664571
    [Abstract] [Full Text] [Related]

  • 19. [Prevention of thromboembolism in patients operated on for hip prosthesis].
    Cremonese M, Rigon N, Ratti G, Pojana A, Todesco A, Sartore A.
    Minerva Med; 1988 May 15; 79(5):367-72. PubMed ID: 3287226
    [Abstract] [Full Text] [Related]

  • 20. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E, Sardina M, Prior M, De Marchi S, Zannoni M, Bianchini C.
    Eur Rev Med Pharmacol Sci; 1998 May 15; 2(2):53-9. PubMed ID: 10229559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.